Editing LSD (section)

===Psychedelic therapy===
{{See also|Psychedelic therapy}}

In the 1950s and 1960s, LSD was used in psychiatry to enhance psychotherapy, known as [[psychedelic therapy]]. Some psychiatrists, such as [[Ronald A. Sandison]], who pioneered its use at [[Powick Hospital]] in England, believed LSD was especially useful at helping patients to "unblock" repressed subconscious material through other [[psychotherapeutic]] methods,<ref>Cohen, S. (1959). "The therapeutic potential of LSD-25". ''A Pharmacologic Approach to the Study of the Mind'', p. 251–258.</ref> and also for treating alcoholism.<ref>{{cite journal |title=Use of d-Lysergic Acid Diethylamide in the Treatment of Alcoholism |journal=Q. J. Stud. Alcohol |volume=20 |pages=577–590 |vauthors=Chwelos N, Blewett DB, Smith CM, Hoffer A |date=1959 |issue=3 |doi=10.15288/qjsa.1959.20.577 |pmid=13810249 |url=http://www.erowid.org/references/texts/show/1852docid1733 |access-date=June 20, 2012 |archive-url=https://web.archive.org/web/20210224135151/https://www.erowid.org/references/texts/show/1852docid1733 |archive-date=February 24, 2021 |url-status=live}} Via {{cite web |title=Abstract |url=http://www.hofmann.org/papers/blewett_1.html |access-date=February 22, 2012 |url-status=live |archive-url=https://web.archive.org/web/20120203022019/http://www.hofmann.org/papers/blewett_1.html |archive-date=February 3, 2012 |website=Hofmann.org}}</ref><ref>{{Cite journal |vauthors=Frood A |date=2012-03-09 |title=LSD helps to treat alcoholism |journal=Nature News |url=http://www.nature.com/news/lsd-helps-to-treat-alcoholism-1.10200 |doi=10.1038/nature.2012.10200 |s2cid=137367650 |access-date=December 25, 2020 |archive-date=March 8, 2021 |archive-url=https://web.archive.org/web/20210308135250/https://www.nature.com/news/lsd-helps-to-treat-alcoholism-1.10200 |url-status=live}}</ref> One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing [[self-acceptance]] and self-surrender,"<ref name="Use of d-lysergic acid diethylamide"/> presumably by forcing the user to face issues and problems in that individual's psyche.

Two recent reviews concluded that conclusions drawn from most of these early trials are unreliable due to serious [[methodological]] flaws. These include the absence of adequate [[control groups]], lack of follow-up, and vague criteria for [[therapeutic]] outcome.  In many cases, studies failed to convincingly demonstrate whether the drug or the therapeutic interaction was responsible for any beneficial effects.<ref>{{cite journal |vauthors=Vollenweider FX, Kometer M |title=The neurobiology of psychedelic drugs: implications for the treatment of mood disorders |journal=Nature Reviews. Neuroscience |volume=11 |issue=9 |pages=642–51 |date=September 2010 |pmid=20717121 |doi=10.1038/nrn2884 |s2cid=16588263}}</ref><ref>{{cite journal |vauthors=Baumeister D, Barnes G, Giaroli G, Tracy D |title=Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles |journal=Therapeutic Advances in Psychopharmacology |volume=4 |issue=4 |pages=156–69 |date=August 2014 |pmid= 25083275 |pmc=4104707 |doi=10.1177/2045125314527985}}</ref>

In recent years, organizations like the [[Multidisciplinary Association for Psychedelic Studies]] (MAPS) have renewed clinical research of LSD.<ref name="new research"/>

It has been proposed that LSD be studied for use in the therapeutic setting, particularly in anxiety.<ref name=":5"/><ref name=":6"/><ref name="clinicalLSD">{{cite journal |vauthors=Liechti ME |title=Modern Clinical Research on LSD |journal=Neuropsychopharmacology |volume=42 |issue=11 |pages=2114–2127 |date=October 2017 |pmid=28447622 |pmc=5603820 |doi=10.1038/npp.2017.86}}</ref><ref>{{Cite news |title=Psychedelics are transforming the way we understand depression and its treatment |date=April 20, 2021 |newspaper=The Guardian |vauthors=Carhart-Harris R |url=https://www.theguardian.com/commentisfree/2021/apr/20/psychedelics-depression-treatment-psychiatry-psilocybin |access-date=16 May 2021 |archive-url=https://web.archive.org/web/20210611212734/https://www.theguardian.com/commentisfree/2021/apr/20/psychedelics-depression-treatment-psychiatry-psilocybin|archive-date=June 11, 2021|url-status=live}}</ref> In 2024, the FDA designated a form of LSD as a breakthrough therapy to treat [[generalized anxiety disorder]] which is being developed by [[MindMed Inc.|MindMed]].<ref>{{Cite web | vauthors = Terry K |date=2024-03-26 |title=FDA Opens the Door to Clinical Use of LSD |url=https://www.webmd.com/mental-health/news/20240326/fda-opens-the-door-clinical-use-lsd |access-date=2024-05-25 |website=WebMD |language=en |archive-date=May 25, 2024 |archive-url=https://web.archive.org/web/20240525075810/https://www.webmd.com/mental-health/news/20240326/fda-opens-the-door-clinical-use-lsd |url-status=live }}</ref>